

Ref. No: 781
From: Josh Lowth josh.lowth@pharmaxo.com
Date: 31/05/23
Subject: homecare medicines and services

REQUEST

How many patients are currently registered with your Trust who are receiving or are set to receive high-tech* homecare medicines and services?

Please provide this **broken down by the treatment they are receiving or are set to receive.**

Please provide this in Excel format by email.

*With high-tech defined as in the [2011 Mark Hackett report](#). That is:

- Injectable therapy, e.g. intravenous, subcutaneous or intramuscular route
- Compounded prescription medicines whether administered by the patient or a Healthcare Professional
- Oral therapies that require significant support such as blood level monitoring or special storage requirements

RESPONSE

We have <5 patients currently on what we would define as high-tech homecare – being treated with S/C Immunoglobulin.

We are unable to provide precise figures when those figures refer to individuals in volumes of 5 or less due to the risk that individuals will be re-identified, as we are required to protect their identity under the General Data Protection Regulations & Data Protection Act 2018. In such circumstances sections 40(2) and (3) of the Freedom of Information Act apply. In this case, our view is that disclosure would breach the first data protection principle. This states that personal data should be processed “lawfully, fairly and in a transparent manner”. It is the lawful aspect of this principle which, in our view, would be breached by disclosure. In such circumstances section 40 confers an absolute exemption on disclosure.

